How I approach iron deficiency with and without anemia. Issue 3 (4th November 2018)

• Record Type: Journal Article
• Authors: Powers, Jacquelyn M.; O'Brien, Sarah H.
• Is Part Of: Pediatric blood & cancer. Volume 66:Issue 3(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-11-04
• Subjects: hepcidin -- inflammation -- intravenous -- nutritional -- therapy; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27544
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Iron deficiency anemia remains a common referral to the pediatric hematology–oncology subspecialist. Improved understanding of iron homeostasis, including the effects of the regulatory hormone hepcidin, recent adult and pediatric clinical trial data, as well as the availability of safer formulations of intravenous iron, have resulted in additional considerations when making treatment recommendations in such patients. Young children and adolescent females remain the most commonly affected groups, but children with complex medical or chronic inflammatory conditions including comorbid gastrointestinal disorders also require special consideration.